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Abstract: Olfactory neuroblastoma (ONB) is a rare cancer originating
in the olfactory epithelium of the nasal vault. The recurrence rate of
ONB is high, as the standard treatment of surgery followed by radio-
therapy and/or chemotherapy is usually unsuccessful. The use of
targeted therapy based on individual genomic variations after cancer
relapse has not been reported. Here, we present the case of a 44-year-old
man who was diagnosed with recurrent ONB and treated with a regimen
developed using whole exome sequencing. Potential targets were first
identified and then matched to appropriate drugs. Gene mutations in the
genes encoding EGFR, FGFR2, KDR, and RET were discovered in the
patient’s tumor tissue by whole exome sequencing and the patient was
treated with a combination of the targeted drugs cetuximab and suni-
tinib. Five days after treatment, enhancement magnetic resonance
imaging showed a 65% reduction in tumor size, and the Visual analog
scale headache scores went down to 2/10 from 10/10. Repeat imaging at
1 month showed a complete response.
This study represents the first demonstration of an effective person-
alized treatment of ONB by targeted drugs, and sheds light on how
precision medicine can be used to treat recurrent ONB that fails to
respond to routine tumor resection, radiotherapy, and/or chemotherapy.
(Medicine 95(18):e3536)
Abbreviations: CR = complete response, MRI = magnetic
resonance imaging, ONB = olfactory neuroblastoma, VAS =
visual analog scale, WES = whole exome sequencing.
INTRODUCTION
O lfactory neuroblastoma (ONB) is also called esthesioneur-oblastoma, which is a rare and slow-growing malignant
tumor arising in the olfactory epithelium located in the upper
part of nasal cavities, the ectopic sphenoclival part,1 or the
sphenoid sinus.2 ONB comprises 3% to 5% of nasal cancers
with an incidence of 1 per 2.5 million.3 The etiology of ONB is
unclear. The recurrence rate and mortality of ONB remain high.
Patients commonly complain of epistaxis, nasal obstruction,
and olfactory and ophthalmic disturbances, as well as cranio-
facial pain. Some patients present with florid Cushing syndrome
that is secondary to ONB,4 or paraneoplastic syndromes and
ectopic adrenocorticotropic hormone syndrome.5 A diagnosis of
ONB may be established by histopathology and confirmed by
immunohistochemistry. The incidence of cervical lymph node
metastasis in ONB is variable, and few reports have been
published concerning retropharyngeal lymph node metastasis
from ONB.6 There is no defined treatment protocol for this
disease. Surgical resection combined with postoperative radio-
therapy has been described as the standard of care for primary
site tumor.7 However, the optimal treatment continues to be
controversial because of the rarity of the disease. Targeted
therapy with either small molecule or monoclonal antibody
drugs in guide of genomics has not been reported. In the present
case, a patient diagnosed with ONB had gone through 3 rounds
of transnasal endoscopic surgery followed by radiotherapy
(60Gy) and chemotherapy, but presented with a recurrence
of ONB 5 months after this standard treatment regimen. Identi-
fication of genomic variations in the tumor tissue made via
whole exome sequencing led to the development of a targeted
therapy regimen using a combination of cetuximab and suni-
tinib. The clinical outcome of this new approach to the treat-
ment of ONB is reported.
Case Report
A 44-year-old male was diagnosed with ONB and under-
went an operation on August 2014. He complained of nasal
obstruction, rhinorrhea, and intermittent epistaxis starting 8
months previous to this, and of cacosmia for 1 day. Dark red
neoplasm located in the patient’ right nasal cavity was observed.
Computed tomography scan further clearly showed the invasion
of multiple structures including anterior skull base, orbit, frontal
sinus, ethmoid sinus, maxillary sinus, sphenoid sinus, and nasal
septum (Figure 1). Pathological results showed that the tumor
cells were ONB (Figure 2 and Figure 3).
The patient refused orbital exenteration, but accepted
endoscope-assisted tumor radical excision. After the operation,
he received radiotherapy of 60Gy in fractions of 2Gy and 3
courses of chemotherapy, including ifosfamide (IV, once a day,
3 g daily for 5 days), cisplatin (IV, once a day, 45 g daily for 3
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days), and etoposide (IV, once a day, 0.11 g daily for 5 days),
but refused continued chemotherapy because of serious side
effects including arthralgia, serious nausea and vomiting, oral
ulcer, and hair loss.
Five months after postoperative treatment was discontin-
ued, the patient presented with complaints of headache and
abulging right eye with decreased vision for 1 day. Examination
showed that he had loss of vision, eyeball fixation, and ble-
phroptosis of the right eye. Visual analog scale (VAS) scores of
headache pain were 10/10. Cerebral enhancement magnetic
resonance imaging (MRI) distinctly showed that there was a
lesion occupying the right temporal lobe space (size:
15.8 13.6 14.3mm). Tumors recurred and affected the
nearby extraocular muscles and the optic nerve (Figure 4A, D).
Given the failure of standard radiotherapy and chemother-
apy after tumor resection, we decided to explore the options for
targeted therapy for this patient. Whole exome sequencing
(WES) was employed to detect the target gene mutations from
patient tumor/normal tissue pairs on the Illumina NextSeq500
sequencing platform and using a TruSeq Rapid Capture Exome
Kit for library construction. The WES data were then analyzed
using OncoDecoderTM (Genomic Future, Inc). The significantly
mutated cancer-related genes that were identified in tumor
tissue included EGFR, KDR, FGFR2, and RET (Table 1).
Specifically, we found a missense mutation p.Arg521Lys
in exon13 of EGFR, missense mutations p.Gln472His (exon11)
and p.Val297lle (exon7) in KDR, a missense mutation
p.Met186Thr in exon5 of FGFR2, and a missense mutation
p.Met1009Thr in exon 18 of RET. Additionally, the KRAS gene
was identified as wild type. Quantitative real-time polymerase
chain reaction confirmed the overexpression of EGFR and KDR
genes in the tumor tissue.
Based on these findings, we carefully screened the cur-
rently available targeted drugs that act on the list of mutated
cancer-related genes and that are used in head and neck cancers.
We determined a treatment regimen of a combination of
cetuximab and sunitinib, wherein cetuximab is a targeted drug
for EGFR and sunitinib for KDR, FGFR2, and RET. The ethics
committee of the Affiliated Zhongshan Hospital of Dalian
University approved the study. The patient received concurrent
cetuximab (IV, once per week, 300mg each time for 4 weeks,
initial dose is 600mg) and sunitinib (PO, once a day, 50mg
daily for 4 weeks) treatment. Five days later, enhancement MRI
revealed right that the lesion occupying the right temporal lobe
space had shrunk to a small hypointense area (size:
12.6 9.1 9.3mm). VAS scores of headache pain were down
to 2/10, although there was still loss of vision, eyeball fixation,
and blephroptosis (Figure 4 B, E). Red Erythra without itch
appeared 10 days after cetuximab was administered to the
patient and disappeared completely in 2 weeks. The patient
was also found in slightly feeble condition, which was con-
firmed by low potassium in serum, and symptom was disap-
peared after potassium chloride intake. Oral ulcer healed but not
hair loss because of early chemotherapy. After he was given the
third dosage of cetuximab, MRI showed that the right temporal
lobe space lesions had completely disappeared (Figure 4C, F).
FIGURE 1. Paranasal sinus computed tomography scan shows paranasal sinus involvement (A), skull base erosion (B), orbit infiltration and
intracranial involvement (C).
FIGURE 2. Microscopically, sheets or discrete nests or lobules of small round cells slightly larger than lymphocytes are present, which are
often compartmentalized into nodules by thin fibrous septa. (A) H&E 100. (B) H&E 400.
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As we prepared the final draft of our manuscript, the patient
remains in stable state, and it has been >4 months since he was
clinically cured of ONB.
DISCUSSION
The rate of neck recurrence in ONB is close to 15%, among
those patients who developed regional metastases, the mortality
is 60%, and the overall mortality is 32%.8 Determining the
optimal treatment scenario for recurrent ONB is challenging. A
combination of endoscopic/open surgery, radiotherapy, and/or
chemotherapy has been considered as standard care for ONB.
Concurrent treatment with neoadjuvant and adjuvant che-
motherapy has also been described,9 but the impacts on clinical
outcomes remain unknown. Unfortunately, the traditional treat-
ment regimens often fail for recurrent and metastatic ONB
cases. Moreover, some patients may refuse to take the standard
protocols because of their intolerance of radiation and/or che-
motherapy, like the patient in our case. Most recently, genome-
based precision medicine has drawn a great deal of attention
from oncologists. Several studies have shown that the use of
targeted medicines can result in either a complete response (CR)
or a significant improvement in the quality of life of patients
with a variety of cancers.10–12 It is widely accepted that one of
the biggest advantages of targeted drugs is their high specificity
and low toxicity. The targeted drugs used in this treatment are
examples of the 2 basic types of targeted drugs. Sunitinib is
an example of small molecule-targeted drug,13 it exerts its
antitumor effects by inhibition of a wide spectrum of
receptor tyrosine kinases, including vascular endothelial growth
factor (VEGF) receptors (VEGFR2/KDR), fibroblast growth
factor receptors (FGFR1 and FGFR2), platelet-derived
growth factor receptors (PDGFRA and PDGFRB), fetal liver
tyrosine kinase receptor (FLT1, FLT3, and FLT4), RET, and c-
Kit.14–16 Sunitinib was approved by Food and Drug Adminis-
tration (FDA) in 2011 for treatment of metastatic renal cell
carcinoma, metastatic or unresectable gastrointestinal stromal
tumors (GIST), and unresectable or metastatic pancreatic neuro-
endocrine tumors. Cetuximab17 is an example of the class of
biological conjugates. It is a monoclonal antibody to the
epidermal growth factor receptor (EGFR). Cetuximab has been
approved for treatment of head and neck cancers by US FDA in
2004 and has been used to treat squamous carcinomas of the
head and neck and colorectal cancers (CRCs) with wild-type
KRAS. In a previous study by Preusser et al18 sunitinib showed
significant improvement of clinical symptoms and disease
stabilization to an ONB patient, who had positive staining of
PDGFRB in the tumor tissue specimen by immunohistochem-
istry. However, to the best of our knowledge, personalized
treatment of ONB with targeted drugs based on the patient’s
genomic variations has not been reported.
To explore the opportunity and potential benefit of targeted
therapy for advanced and recurrent ONB, we sequenced the
whole exomes of the tumor/normal tissues of the patient in our
genetic test laboratory, and identified several significantly
mutated cancer genes including EGFR, VEGFR2/KDR,
FGFR2, and RET (Table 1). Interestingly, the R521K poly-
morphism of the EGFR gene was associated with a longer
progression-free survival in CRC patients treated with cetux-
imab.19 Therefore, it is perhaps not surprising to see that the
patient showed a striking response to a cetuximab plus sunitinib
treatment regimen (Figure 4). One month after the target
therapy, the patient showed a CR. As we prepared the final
draft of our manuscript, the patient remains in stable state.
Follow-up care has been established for the patient and an
update of clinical outcomes is warranted. As ONB is a rare
disease, collaborative efforts for a cohort study is desirable to
further prove the effectiveness of targeted therapy for ONB.
CONCLUSIONS
Surgery followed by radiation and chemotherapy is the
current standard of care for ONB and fails frequently with a
high risk of morbidity and severe side effects. Genome-based
FIGURE 3. Immunohistochemically, olfactory neuroblastomas stain for Neuron Specific Enolase (NSE) (A, B). The supporting or
sustentacular cells tested positive for S-100 protein (C, D).
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targeted therapy for recurrent and late-stage ONB is certainly an
option in terms of its promising clinical response, and hence
deserves further investigation in a prospective clinical trial.
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